Cancer cure found? Scientists create a new mRNA vaccine that triggers strong anticancer immune response against tumours
Towards a universal cancer vaccine
Live Events
Building on past research
(You can now subscribe to our
(You can now subscribe to our Economic Times WhatsApp channel
In a major development in cancer research , scientists at the University of Florida have created an experimental mRNA vaccine that stimulates the immune system to attack tumours. According to a study published in Nature Biomedical Engineering, the vaccine, when used alongside immune checkpoint inhibitors, produced a strong antitumor effect in mice.The vaccine does not target specific cancer proteins. Instead, it activates the immune system in the same way it would respond to a virus. Researchers found that the vaccine increased the levels of a protein called PD-L1 within tumours, making them more sensitive to immunotherapy.Dr. Elias Sayour, a paediatric oncologist at UF Health and the lead researcher, said this development could lead to a new form of cancer treatment that does not rely entirely on surgery, radiation, or chemotherapy. The research was supported by the National Institutes of Health and other leading institutions.'This paper describes a very unexpected and exciting observation: that even a vaccine not specific to any particular tumor or virus – so long as it is an mRNA vaccine – could lead to tumor-specific effects,' said Sayour, who is also the principal investigator at the RNA Engineering Laboratory at UF's Preston A. Wells Jr. Center for Brain Tumor Therapy.Sayour added, 'This finding is a proof of concept that these vaccines potentially could be commercialised as universal cancer vaccine s to sensitise the immune system against a patient's individual tumor.'The research challenges the two current approaches in cancer-vaccine development: targeting common proteins found in cancer patients or customising a vaccine for each patient. This study suggests a third path that focuses on stimulating a broad immune response.'This study suggests a third emerging paradigm,' said Duane Mitchell, MD, PhD, a co-author of the paper. 'What we found is by using a vaccine designed not to target cancer specifically but rather to stimulate a strong immunologic response, we could elicit a very strong anticancer reaction. And so this has significant potential to be broadly used across cancer patients, even possibly leading us to an off-the-shelf cancer vaccine .'Sayour has spent more than eight years developing mRNA-based cancer vaccines using lipid nanoparticles. These vaccines work by delivering messenger RNA (mRNA), a molecule that instructs cells to make specific proteins, into the body to prompt an immune reaction.Last year, Sayour's lab conducted a human trial using a personalised mRNA vaccine made from a patient's own tumour cells. The treatment quickly activated the immune system to fight glioblastoma, a deadly brain cancer. The new study builds on that work by testing a generalised mRNA vaccine, not specific to any virus or cancer mutation.The formulation of this new vaccine is similar to the technology used in COVID-19 vaccines but is designed to prompt a general immune response rather than target a specific protein like the COVID spike protein.If the vaccine shows similar results in future human studies, it could lead to a universal tool in the fight against cancer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 hours ago
- Time of India
Novo Nordisk's Wegovy, Mounjaro sales in India double on month in July
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Sales of Danish drugmaker Novo Nordisk 's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month earlier, data from research firm Pharmarack showed on for the blockbuster anti-obesity drugs , which help control blood sugar and slow digestion, has been on an upswing in the world's most populous of Wegovy, launched locally in June, more than doubled to 5,000 units or 70 million rupees ($798,230) in July, the data sales also doubled month-on-month to 157,000 units or 470 million rupees."Though Wegovy has a strong prescriber base because of Rybelsus, substantial promotion may be needed to reach the Mounjaro patient base for the injectable market," Pharmarack's Vice President (Commercial) Sheetal Sapale said in a India, Novo has been selling oral semaglutide pills under the brand name Rybelsus since 2022 for type 2 diabetes Mounjaro's sales have soared 15 times since March, when the drug was launched in India.($1 = 87.6790 Indian rupees)
Economic Times
5 hours ago
- Economic Times
Alzheimer's symptoms and memory loss reverses by lithium supplement, offering new hope for cure
A Harvard Medical School study reveals that lithium orotate supplementation effectively reverses Alzheimer's-like memory loss and brain pathology in mice. The research highlights lithium depletion in Alzheimer's brains due to amyloid plaque binding. Supplementation restores lithium levels, reduces plaque burden, and improves cognitive function, offering a promising therapeutic avenue for Alzheimer's disease. Tired of too many ads? Remove Ads Understanding Alzheimer's and the role of lithium What the study found: Lithium depletion in Alzheimer's Tired of too many ads? Remove Ads How lithium deficiency affects the brain Healthy mice deprived of lithium showed early signs of brain aging, increased inflammation, and the formation of amyloid plaques and tau pathology. Alzheimer's-model mice on a lithium-deficient diet experienced a more rapid buildup of plaques, worsened memory decline, and impaired function of microglia, reducing the brain's ability to clear toxic proteins. The revolutionary solution: Lithium orotate supplement Alzheimer's mice treated with lithium orotate showed up to a 70% reduction in amyloid plaque burden. Memory tests revealed treated mice regained significant cognitive abilities, performing tasks they previously failed. Crucially, the lithium orotate supplement did not show toxic effects at the doses used, suggesting it could be safe for long-term use. Why this matters From mice to humans A groundbreaking study from Harvard Medical School , published in Nature , has unveiled that lithium orotate supplementation can reverse Alzheimer's-like memory loss and brain pathology in mice, suggesting a promising new therapeutic cure for this devastating neurodegenerative disease affecting around 55 million people disease, a progressive brain disorder characterized by memory loss and cognitive decline, has long eluded curative disease is marked by the accumulation of toxic proteins in the brain — primarily amyloid beta plaques and tau tangles — that disrupt neuron function and trigger inflammation. This causes neurons to die over time, leading to memory loss and cognitive is a naturally occurring mineral that has been used for decades in psychiatric medicine, especially to treat bipolar disorder. Importantly, lithium also supports essential cellular processes in the brain, helping to regulate signaling pathways, reduce oxidative stress, and protect neurons from new research uncovers a previously unknown problem: in the brains of individuals with Alzheimer's, lithium levels drop significantly. This happens because amyloid beta plaques physically bind lithium ions, sequestering them away from neurons and other brain cells that need lithium to function lithium is trapped inside plaques, nearby neurons and microglia — the brain's immune cells responsible for clearing out waste proteins — become lithium-deficient. This deficiency worsens plaque buildup and disrupts brain cleanup mechanisms, accelerating disease understand the impact, researchers studied mice with genetic modifications that cause Alzheimer's-like symptoms. They experimented with diets lacking lithium and observed that:This strongly suggested lithium deficiency is not just a side effect but an active driver of disease scientists then tested whether supplementing lithium could reverse these problems. They used a compound called lithium orotate, which is chemically structured to bypass the plaque sequestration that traps regular lithium salts, allowing lithium to effectively reach and nourish brain results were striking:Previous Alzheimer's treatments have largely focused on removing amyloid plaques or targeting other symptoms without restoring brain cell health. This new approach suggests that restoring lithium levels directly supports the brain's natural defense and repair systems, allowing neurons and immune cells to function normally and remove toxic since lithium is a naturally occurring nutrient found in food, water, and already used medically, translating these findings into human trials could be faster and more cost-effective compared to developing entirely new these findings are highly promising, scientists emphasize that more research is needed to determine if lithium orotate will have the same benefits and safety in people with Alzheimer's. Clinical trials are required to find optimal dosing, evaluate long-term effects, and understand potential these results translate to humans, we could see more accessible, affordable, and safe treatments emerging, potentially transforming the outlook for millions suffering from this devastating disease.
The Hindu
5 hours ago
- The Hindu
Major climate change-GDP study under review after facing challenge
A blockbuster study published in top science journal Nature last year warned that unchecked climate change could slash global GDP by a staggering 62 percent by century's end, setting off alarm bells among financial institutions worldwide. But a re-analysis by Stanford University researchers in California, released Wednesday (August 6, 2025), challenges that conclusion — finding the projected hit to be about three times smaller and broadly in line with earlier estimates, after excluding an anomalous result tied to Uzbekistan. The saga may culminate in a rare retraction, with Nature telling AFP it will have "further information to share soon" — a move that would almost certainly be seized upon by climate-change skeptics. Both the original authors — who have acknowledged errors — and the Stanford team hoped the transparency of the review process would bolster, rather than undermine public confidence in science. Climate scientist Maximilian Kotz and co-authors at the renowned Potsdam Institute for Climate Impact Research (PIK), published the original research in April 2024, using datasets from 83 countries to assess how changes in temperature and precipitation affect economic growth. Influential paper It became the second most cited climate paper of the year, according to the UK-based Carbon Brief outlet, and informed policy at the World Bank, International Monetary Fund, U.S. federal government and others. AFP was among numerous media outlets to report on it. Yet the eye-popping claim that global GDP would be lowered by 62 percent by the year 2100 under a high emissions scenario soon drew scrutiny. "That's why our eyebrows went up because most people think that 20 percent is a very big number," scientist and economist Solomon Hsiang, one of the researchers behind the re-analysis, also published in Nature, told AFP. When they tried to replicate the results, Hsiang and his Stanford colleagues spotted serious anomalies in the data surrounding Uzbekistan. Specifically, there was a glaring mismatch in the provincial growth figures cited in the Potsdam paper and the national numbers reported for the same periods by the World Bank. "When we dropped Uzbekistan, suddenly everything changed. And we were like, 'whoa, that's not supposed to happen,'" Hsiang said. "We felt like we had to document it in this form because it's been used so widely in policy making." The authors of the 2024 paper acknowledged methodological flaws, including currency exchange issues, and on Wednesday uploaded a corrected version, which has not yet been peer-reviewed. "We're waiting for Nature to announce their further decision on what will happen next," Kotz told AFP. He stressed that while "there can be methodological issues and debate within the scientific community," the bigger picture was unchanged: climate change will have substantial economic impacts in the decades ahead. Undeniable climate impact Frances Moore, an associate professor in environmental economics at the University of California, Davis, who was not involved in either the original paper or the re-analysis, agreed. She told AFP the correction did not alter overall policy implications. Projections of an economic slowdown by the year 2100 are "extremely bad" regardless of the Kotz-led study, she said, and "greatly exceed the costs of reducing greenhouse gas emissions to stabilize the climate, many times over." "Future work to identify specific mechanisms by which variation in climate affects economic output over the medium and long-term is critical to both better understand these findings and prepare society to respond to coming climate disruption," she also noted. Asked whether Nature would be retracting the Potsdam paper, Karl Ziemelis, the journal's physical sciences editor, did not answer directly but said an editor's note was added to the paper in November 2024 "as soon as we became aware of an issue" with the data and methodology. "We are in the final stages of this process and will have further information to share soon," he told AFP. The episode comes at a delicate time for climate science, under heavy fire from the U.S. government under President Donald Trump's second term, as misinformation about the impacts of human-driven greenhouse gases abounds. Yet even in this environment, Hsiang argued, the episode showed the robust nature of the scientific method. "One team of scientists checking other scientists' work and finding mistakes, the other team acknowledging it, correcting the record, this is the best version of science."
